The Institut de la Màcula i de la Retina, a benchmark in research into treatments for AMD

It is the first accredited center in Europe for the CHROMA medical trial.

Lampalizumab is the first therapy to show significant efficacy in slowing the progression of Age-Related Macular Degeneration (AMD), which in its dry or atrophic variant, is the leading cause of non-avoidable blindness in the world in people over 50 years of age.

The Phase III trial evaluates the efficacy and safety of Lampalizumab in patients with Geographic Atrophy (GA) and AMD. These trials, called Chroma, will enroll approximately 936 patients at 300 research centers in 24 countries worldwide.

The main objective is to demonstrate a reduction in the rate of GA progression, in addition to focusing on evaluating the impact of Lampalizumab treatment on patients’ visual function.

“Lampalizumab is a milestone in the fight against atrophic AMD. For the first time a drug has demonstrated efficacy in a Phase II study to reduce the progression of deterioration. Phase III is an opportunity for patients who have the potential to improve degeneration. The results of these Phase III trials can confirm these promising results,” says Dr. Jordi Monés, specialist ophthalmologist and member of Top Doctors.

Read Now 👉  Early detection of Macular Degeneration in pharmacies in Catalonia